Quoin receives FDA Fast Track designation for Peeling Skin Syndrome therapy QRX003.

Quoin Pharmaceuticals announced the FDA granted Fast Track designation to QRX003 for Peeling Skin Syndrome, a disease with no approved treatment. This is the second indication for which the serine protease inhibitor has received the designation.